FDAnews
www.fdanews.com/articles/73636-generex-to-study-novel-allergy-therapy

GENEREX TO STUDY NOVEL ALLERGY THERAPY

June 26, 2005

Generex Biotechnology has signed a research collaboration agreement with Stallergenes, a European firm developing immunological treatments for allergy and asthma.

The agreement calls for the firms to initiate studies to test Ii-Key/allergen epitope hybrid peptides to create a novel approach for the control of both dangerous forms of asthma and functionally disabling allergic reactions. A large number of individuals in both North America and Europe suffer from various forms of allergic responses. These range from allergic rhinitis to cat dander, to ragweed hay fever, to potentially fatal asthmatic attacks from bee sting or peanut allergens.